Section 1 of 4Overview

Overview

A synthetic salmon calcitonin medicine with limited, indication-specific FDA uses.

Primary regulatory source

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.

Section 2 of 4Identity and mechanism

Identity and mechanism

Calcitonin receptor activation reduces osteoclast-mediated bone resorption and lowers serum calcium.

PubChem CID 16220016; C145H240N44O48S2; 3431.9 Da.

Section 3 of 4Regulatory label facts

Regulatory label facts

FDA (United States; restricted indication set in current Miacalcin label).

The dose below reproduces a regulator-approved label; it is not a treatment recommendation.

Section 4 of 4Safety boundary

Safety boundary

The label limits use because fracture-reduction efficacy has not been demonstrated and meta-analysis identified a possible increased malignancy risk; hypersensitivity and hypocalcemia also require attention.

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.